Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy

Despite the efficacy of a number of first-line treatments, most patients with advanced-stage non-small cell lung cancer (NSCLC) experience disease progression that warrants further treatment. In this review, we examine the role of novel active agents for patients who progress after first-line therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Manegold, Christian, Adjei, Alex, Bussolino, Federico, Cappuzzo, Federico, Crino, Lucio, Dziadziuszko, Rafal, Ettinger, David, Fennell, Dean, Kerr, Keith, Le Chevalier, Thierry, Leighl, Natasha, Papotti, Mauro, Paz-Ares, Luis, Pérol, Maurice, Peters, Solange, Pirker, Robert, Quoix, Elisabeth, Reck, Martin, Smit, Egbert, Vokes, Everett, van Zandwijk, Nico, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729303/
https://www.ncbi.nlm.nih.gov/pubmed/29435365
http://dx.doi.org/10.1136/esmoopen-2016-000118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729303/
https://www.ncbi.nlm.nih.gov/pubmed/29435365
http://dx.doi.org/10.1136/esmoopen-2016-000118

Ejemplares similares